HomeCompareLMNL vs GBDC

LMNL vs GBDC: Dividend Comparison 2026

LMNL yields 23.53% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.69M in total portfolio value· pulled ahead in Year 3
10 years
LMNL
LMNL
● Live price
23.53%
Share price
$8.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.5K
Annual income
$9,663.72
Full LMNL calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — LMNL vs GBDC

📍 GBDC pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLMNLGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LMNL + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LMNL pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LMNL
Annual income on $10K today (after 15% tax)
$2,000.00/yr
After 10yr DRIP, annual income (after tax)
$8,214.16/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,922,659.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LMNL + GBDC for your $10,000?

LMNL: 50%GBDC: 50%
100% GBDC50/50100% LMNL
Portfolio after 10yr
$10.43M
Annual income
$8,199,463.56/yr
Blended yield
78.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

LMNL
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
-49.8
Piotroski
5/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LMNL buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLMNLGBDC
Forward yield23.53%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$90.5K$20.78M
Annual income after 10y$9,663.72$16,389,263.41
Total dividends collected$55.7K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: LMNL vs GBDC ($10,000, DRIP)

YearLMNL PortfolioLMNL Income/yrGBDC PortfolioGBDC Income/yrGap
1$13,053$2,352.94$12,490$1,790.28+$563.00LMNL
2$16,837$2,870.36$16,522$3,157.73+$315.00LMNL
3← crossover$21,476$3,460.26$23,578$5,898.68$2.1KGBDC
4$27,104$4,124.87$37,115$11,886.75$10.0KGBDC
5$33,867$4,865.30$66,136$26,423.57$32.3KGBDC
6$41,919$5,681.51$137,257$66,491.44$95.3KGBDC
7$51,425$6,572.30$341,734$194,868.54$290.3KGBDC
8$62,561$7,535.33$1,050,788$685,133.02$988.2KGBDC
9$75,507$8,567.24$4,099,314$2,974,971.01$4.02MGBDC
10$90,456$9,663.72$20,775,530$16,389,263.41$20.69MGBDC

LMNL vs GBDC: Complete Analysis 2026

LMNLStock

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Full LMNL Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this LMNL vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LMNL vs SCHDLMNL vs JEPILMNL vs OLMNL vs KOLMNL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.